2023 World Conference on Lung Cancer (Posters)-EP13.01. Study of NLI Use in the First Line of Atezolizumab Plus Chemotherapy

Pdf Summary

The study aimed to analyze the neutrophil-lymphocyte index (NLI) as a prognostic factor in small cell lung cancer (SCLC) patients treated with atezolizumab and chemotherapy. The researchers conducted a multicenter retrospective study including all patients diagnosed with SCLC between October 2021 and November 2022. All patients received first-line treatment with atezolizumab and chemotherapy. Clinical, analytical, and pathological variables were collected.<br /><br />A total of 118 patients were included in the study. The researchers calculated the NLI at baseline (NLI-1) and at the third cycle (NLI-2). They observed that 46% of patients had a high NLI3 at baseline, while 53% had a low NLI3. No significant differences were found in clinical variables between the two subgroups. However, there were significant differences in the levels of leukocytes, monocytes, and lymphocytes between the high and low NLI3 groups.<br /><br />At the third cycle, 71.2% of patients had a high NLI-2, while 28.7% had a low NLI-2. Similar to the baseline NLI, no differences were found in the clinical characteristics, but significant differences were observed in the analytical parameters.<br /><br />The study concluded that the use of NLI at baseline and at the third cycle is not a predictor of survival or response to treatment with immunotherapy plus chemotherapy in SCLC. The median overall survival was 12.5 months, and the progression-free survival was 5 months. No significant differences were found according to the level of NLI3 or NLI-2. The number of cycles of chemotherapy and atezolizumab received also did not differ between the NLI groups.<br /><br />The researchers suggest that more studies are needed in this field to validate their conclusions.

Asset Subtitle

Ruth Alvarez Cabellos

Meta Tag

Speaker Ruth Alvarez Cabellos

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

neutrophil-lymphocyte index

NLI

prognostic factor

small cell lung cancer

SCLC

atezolizumab

chemotherapy

retrospective study

clinical variables

analytical parameters